Interferon beta-1b injection site reactions and necroses

Multiple Sclerosis

Volumn 4, Issue 2, 1998, Pages 70-73

  Gaines, Ann Reed ^a   Varricchio, Frederick ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Interferon beta 1b adverse events

Indexed keywords

INTERFERON BETA SERINE; RECOMBINANT INTERFERON;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; HUMAN; INJECTION SITE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; SEX RATIO; SYMPTOM; TISSUE NECROSIS;

EID: 0347047191     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859800400205     Document Type: Article

References (8)

1. Code of Federal Regulations, 21 CFR 600.80-90. Post-marketing reporting of adverse experiences. US Government Printing Office, 1996: pp 13 - 17.
2. Baum C, Kweder SL, Anello C. (1995). The spontaneous reporting system in the United States. In: Strom, BL (ed.) Pharmacoepidemiology, 2nd ed. New York: John Wiley & Sons, pp 125 - 155.
3. Mohr DC et al. (1997). Treatment of depression improves adherence to Interferon beta-1b therapy for multiple sclerosis. Arch Neurol 54: 531 - 533.
4. Hauser HL. (1994). Multiple sclerosis and other demyelinating diseases. In: Isselbacher KJ, Braunwald AB, Wilson JD, Margin JB, Fauci AS, Kasper DL, (eds.) Harrison's principles of internal medicine, 13th ed. New York: McGraw-Hill, Inc., p 2287.
5. IFNB Multiple Sclerosis Study Group. (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical trials of a multicenter. randomized, double-blind, placebo-controlled trial. Neurology, 43: 655 - 661.
6. Betaseron. Physician's desk reference, 49th ed. Montvale: Medical Economics, 1995: pp 622 - 626.
7. Sheremata WA, Taylor JR, Elgart GW (1995). Severe necrotizing cutaneous lesions complicating treatment with Interferon beta-1b. NEJM 332: 1584.
8. Jonas WB. (1997). Clinical trials for chronic disease. J NIH Research 9: 33 - 39.